MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities and sales of marketab...
    • Proceeds from the revenue share ...
    • Equity-based compensation expens...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Prepaid expenses and other curre...
    • Other non-current assets
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-85,854
-74,111
-69,387
-65,021
Depreciation expense
409
408
406
406
Equity-based compensation expense
16,663
17,155
11,930
11,877
Amortization of discounts on marketable securities
1,741
1,549
1,742
1,620
Non-cash lease expense
999
980
959
940
Non-cash interest expense
1,580
-
-
-
Loss on disposal of property and equipment
-43
-
-
-
Prepaid expenses and other current assets
6,134
2,490
-1,642
2,106
Other non-current assets
2,091
-155
-73
181
Accounts payable
1,843
16
845
-5,302
Operating lease liability
-1,214
-802
-1,004
-992
Accrued expenses
4,117
4,668
-6,411
7,744
Net cash used in operating activities
-71,380
-55,570
-62,689
-54,255
Purchases of marketable securities
552,752
183,244
389,088
107,632
Maturities and sales of marketable securities
170,883
147,895
100,524
125,577
Purchases of property and equipment
-
-
62
0
(purchase) sale of property and equipment
-6
-
-
-
Net cash (used in) provided by investing activities
-381,863
-35,349
-288,626
17,945
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
-
-
324,052
-
Proceeds from issuance of common stock, net of issuance costs
-728
378,169
-
0
Proceeds from issuance of common stock under atm equity offering program, net of issuance costs
-
-
65,582
-
Proceeds from issuance of common stock under the atm facility, net of issuance costs
0
9,552
-
19,382
Proceeds from exercise of options and employee stock purchase plan purchases
14,059
-
4,698
356
Proceeds from exercise of options
-
4,064
-
-
Proceeds from the revenue share agreement (as defined below), net of debt issuance costs
97,750
-
-
-
Net cash provided by financing activities
107,017
411,167
374,950
19,738
Decrease in cash, cash equivalents and restricted cash
-346,226
320,248
23,635
-16,572
Cash, cash equivalents and restricted cash, beginning of period
451,797
131,549
107,914
142,083
Cash, cash equivalents and restricted cash, end of period
105,571
-
-
-
Issuance of common stock upon exercise of stock options for which proceeds had not yet been received
17
-
-
-
Cash and cash equivalents
105,571
-
-
-
Total
105,571
451,797
131,549
107,914
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from the revenueshare agreement (as...$97,750K Proceeds from exercise ofoptions and employee...$14,059K (680.19%↑ Y/Y)Net cash provided byfinancing activities$107,017K (5838.79%↑ Y/Y)Canceled cashflow$728K Decrease in cash, cashequivalents and restricted...-$346,226K (-1867.53%↓ Y/Y)Canceled cashflow$107,017K Maturities and sales ofmarketable securities$170,883K (-29.32%↓ Y/Y)(purchase) sale of propertyand equipment-$6K Equity-based compensationexpense$16,663K (-25.84%↓ Y/Y)Accrued expenses$4,117K (271.04%↑ Y/Y)Accounts payable$1,843K (-60.00%↓ Y/Y)Non-cash interestexpense$1,580K Non-cash lease expense$999K (-43.81%↓ Y/Y)Depreciation expense$409K (-32.51%↓ Y/Y)Loss on disposal ofproperty and equipment-$43K Proceeds from issuance ofcommon stock, net of...-$728K Net cash (used in)provided by investing...-$381,863K (-519.14%↓ Y/Y)Canceled cashflow$170,889K Net cash used inoperating activities-$71,380K (35.41%↑ Y/Y)Canceled cashflow$25,654K Purchases of marketablesecurities$552,752K (279.69%↑ Y/Y)Net loss-$85,854K (29.30%↑ Y/Y)Prepaid expenses andother current assets$6,134K (273.57%↑ Y/Y)Other non-currentassets$2,091K (-74.99%↓ Y/Y)Amortization of discounts onmarketable securities$1,741K (-57.94%↓ Y/Y)Operating lease liability-$1,214K (38.84%↑ Y/Y)

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics, Inc. (APGE)